Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978750 | 0.89 | SLC9A3 (0.39) | SLC9A3 | |
| SCHEMBL979823 | 0.89 | SLC9A3 (0.39) | SLC9A3 | |
| SCHEMBL977341 | 0.89 | SLC9A3 (0.39) | SLC9A3 | |
| Trifluoroacetic Acid SCHEMBL6757086 | 0.88 | SLC9A3 (0.43) | SLC9A3 | |
| SCHEMBL979244 | 0.79 | SLC9A3 (0.33) | SLC9A3 | |
| SCHEMBL4898996 | 0.78 | SLC9A3 (0.36) | SLC9A3 | |
| SCHEMBL4028962 | 0.77 | SLC9A3 (0.46) | SLC9A3 | |
| SCHEMBL4898991 | 0.76 | SLC9A3 (0.36) | SLC9A3 | |
| SCHEMBL4898994 | 0.74 | NPC1 (0.35) | SLC9A3SMN1; SMN2 | |
| SCHEMBL4899001 | 0.74 | NPC1 (0.35) | SLC9A3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868003-B2 | Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | REN, MTNR1B, MTNR1A | SLC9A3 2159/4885F2 786/4885F10 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.